Dual inhibition of CDK4 and CDK6 and the androgen receptor pathway with abemaciclib plus abiraterone did not improve radiographic progression-free survival compared with abiraterone alone in the CYCLONE 2 study population with mCRPC. Safety of the combination was consistent with the previously reported safety of the individual drugs. Additional research is required to identify effective combination therapies for patients with…
[Articles] Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology | | Matthew Smith, Josep Piulats, Tilman Todenhöfer, Jae-Lyun Lee, José Arranz Arija, Laura Mazilu, Arun Azad, Teresa Alonso-Gordoa, Ursula McGovern, Atish Choudhury, Lisa Horvath, Dingwei Ye, Weiqing Han, Hiroyoshi Suzuki, Hiroji Uemura, Rana McKay, Steven Ades, Aude Fléchon, Christopher Pieczonka, Maria S Fernandes, Maarten Hulstijn, Andrew Lithio, Karim Nacerddine, Neeraj Agarwal, on behalf of the CYCLONE 2 investigators
Topics: prostate-cancer, clinical-trials, research